Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02613650	Phase I	Binimetinib + Fluorouracil + Irinotecan + Leucovorin	A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers	Completed	USA	0
NCT03300609	Phase III	Capecitabine Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Fluorouracil + Leucovorin + Panitumumab	5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab	Terminated	USA	0
NCT06625320	Phase III	Fluorouracil + Leucovorin + Liposomal irinotecan Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel RMC-6236	Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)	Recruiting	USA	1
NCT03069950	Phase II	Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver	Withdrawn	USA	0
NCT02573220	Phase I	Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer	Withdrawn	ITA	0
NCT03384940	Phase II	Trastuzumab deruxtecan	DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)	Completed	USA \| ITA \| GBR \| ESP	1
NCT04429542	Phase I	BCA101 BCA101 + Pembrolizumab	Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors	Recruiting	USA \| CAN \| AUS	0
NCT01312857	Phase II	Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine	Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer	Completed	USA	0
NCT02508077	Phase II	Fluorouracil + Irinotecan + Leucovorin Panitumumab	FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer	Terminated	USA	0
NCT05638698	Phase II	Balstilimab + QS21 + TG01 QS21 + TG01	Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA)	Active, not recruiting	USA	0
NCT03867799	Phase II	Nivolumab + Relatlimab	iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer	Active, not recruiting	GBR	0
NCT06299839	Phase I	PAS-004	PAS-004 in Patients With Advanced Solid Tumors	Recruiting	USA \| ROU \| BGR	0
NCT06634875	Phase II	Isunakinra	Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS)	Not yet recruiting	USA	0
NCT06162221	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Pembrolizumab + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Pembrolizumab + RMC-6291	Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC	Recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU	0
NCT02383927	Phase II	Tipifarnib	Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations	Completed	USA \| NLD \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| BEL	1
NCT06328738	Phase I	ELVN-002 + Eribulin + Trastuzumab Capecitabine + ELVN-002 + Trastuzumab ELVN-002 + Paclitaxel + Trastuzumab Capecitabine + ELVN-002 + Oxaliplatin + Trastuzumab ELVN-002 + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab ELVN-002 + Trastuzumab	ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer	Recruiting	USA \| NLD \| ITA \| FRA \| ESP \| BEL	1
NCT02296242	Phase Ib/II	Ulixertinib	Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes	Completed	USA	0
NCT05012618	Phase I	LUNA18	A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	Recruiting	USA	1
NCT03190915	Phase II	Trametinib	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	Active, not recruiting	USA	0
NCT03719690	Phase II	Tipifarnib	Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)	Completed	USA \| NOR \| NLD \| ITA \| GRC \| GBR \| ESP \| DNK \| DEU \| BEL \| AUT \| AUS	4
NCT06026410	Phase I	Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806	KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001)	Recruiting	USA	0
NCT03875820	Phase I	Defactinib + RO5126766	Phase I Trial of Defactinib and VS-6766. (FRAME)	Active, not recruiting	GBR	0
NCT03698994	Phase II	Ulixertinib	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT05217446	Phase II	Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)	Active, not recruiting	USA \| SWE \| SVK \| POL \| NOR \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BEL \| AUS	0
NCT03415126	Phase I	ERAS-007	A Study of ASN007 in Patients With Advanced Solid Tumors	Completed	USA	0
NCT01907815	Phase II	Trametinib + Uprosertib	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia	Terminated	USA	0
NCT05983367	Phase II	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RGX202	A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer	Active, not recruiting	FRA \| ESP \| BEL	0
NCT02747537	Phase II	Irinotecan + Sorafenib	Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan	Withdrawn		0
NCT01449058	Phase Ib/II	Alpelisib + Binimetinib	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Completed	USA \| ITA \| GBR \| FRA \| ESP \| CHE \| AUS	0
NCT05706779	Phase II	Cetuximab + Encorafenib	Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF)	Recruiting	FRA	0
NCT03919292	Phase Ib/II	Divalproex sodium + Neratinib	Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca	Recruiting	USA	0
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT03043313	Phase II	Trastuzumab + Tucatinib Tucatinib	Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer	Completed	USA \| ITA \| FRA \| ESP \| BEL	0
NCT03714958	Phase I	Siremadlin + Trametinib	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)	Completed	FRA	0
NCT06287463	Phase Ib/II	DCC-3084	Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway	Recruiting	USA	0
NCT04425239	Phase II	Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE)	Completed	ITA	0
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT03051035	Phase I	KO-947	First-in-Human Study of KO-947 in Non-Hematological Malignancies	Terminated	USA \| ESP	0
NCT03181100	Phase II	Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer	Active, not recruiting	USA	0
NCT04211337	Phase III	Vandetanib Cabozantinib Selpercatinib	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS	5
NCT04985604	Phase Ib/II	Pimasertib + Tovorafenib Tovorafenib	Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors	Active, not recruiting	USA \| FRA \| ESP \| CAN \| BEL \| AUS	1
NCT02857270	Phase I	LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996	A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	Completed	USA \| FRA \| AUS	1
NCT04808362	Phase Ib/II	OMO-103	Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure)	Terminated	ESP	0
NCT03496766	Phase II	Tipifarnib	Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS	Terminated	ESP	0
NCT04566393	Expanded access	Ulixertinib	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies	Available	USA	0
NCT05554367	Phase II	Binimetinib + Palbociclib	Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT04072198	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin	Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR)	Unknown status	ITA	0
NCT04145297	Phase I	Hydroxychloroquine + Ulixertinib	Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH)	Completed	USA	0
NCT03913026	Phase II	ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa	UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia	Active, not recruiting	CAN	0
NCT04515394	Phase II	Cetuximab + Tepotinib	Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| CZE \| BEL	1
NCT03213691	Phase II	Selumetinib	Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT01737502	Phase Ib/II	Auranofin + Sirolimus	Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer	Completed	USA	0
NCT04511845	Phase I	SPYK04	A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	Active, not recruiting	USA	1
NCT02224781	Phase III	Ipilimumab + Nivolumab Dabrafenib + Trametinib	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	Active, not recruiting	USA	0
NCT06533059	Phase I	ALTA-2618	A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors	Recruiting	USA	0
NCT06096974	Phase I	TEB-17231	Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS	Not yet recruiting	USA	0
NCT05564403	Phase II	Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	Recruiting	USA	0
NCT05886920	Phase I	D3S-002	Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations	Recruiting	USA \| AUS	1
NCT06509126	Phase III	Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE-2)	Recruiting	ITA	0
NCT05057013	Phase Ib/II	HMBD-001	HMBD-001 in Advanced HER3 Positive Solid Tumours	Recruiting	GBR	0
NCT05312398	Phase II	Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin	CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen	Active, not recruiting	ITA	0
NCT02292758	Phase II	Bevacizumab + Cetuximab + Irinotecan Cetuximab + Irinotecan	Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer	Completed	USA	0
NCT05062889	Phase II	Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Trifluridine-tipiracil hydrochloride Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib	Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (ERASE-CRC)	Recruiting	ITA	0
NCT04892017	Phase Ib/II	DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib	A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors	Recruiting	USA	0
NCT04310176	Phase II	Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil Bevacizumab + Fluorouracil + Valproic acid Bevacizumab + Capecitabine + Valproic acid Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Valproic acid Bevacizumab + Capecitabine + Oxaliplatin + Valproic acid	Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION)	Recruiting	ITA	0
NCT05253651	Phase III	Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin	A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)	Recruiting	USA \| SVK \| POL \| NOR \| NLD \| ITA \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	6
NCT03983993	Phase II	Niraparib + Panitumumab	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect)	Active, not recruiting	USA	0
NCT03244956	Phase II	Trametinib Dabrafenib + Trametinib	Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE)	Unknown status	FRA	0
NCT05221320	Phase II	Hydroxychloroquine + Ulixertinib	Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies	Terminated	USA	0
NCT05503797	Phase II	Cobicistat + PLX8394 PLX8394	A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations	Recruiting	USA \| SWE \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN	1
NCT01885195	Phase II	Binimetinib	MEK162 for Patients With RAS/RAF/MEK Activated Tumors	Completed	USA	0
NCT04854434	Phase II	Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor	A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations	Terminated	USA	0
NCT04776655	Phase III	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb)	Unknown status	ITA	0
NCT05585320	Phase Ib/II	IMM-1-104	A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors	Recruiting	USA	0
NCT05831995	Phase I	ABM-168	Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.	Recruiting	USA	0
NCT04800822	Phase I	PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892	PF-07284892 in Participants With Advanced Solid Tumors	Terminated	USA	0
NCT06445062	Phase Ib/II	Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236 Gemcitabine + Nab-paclitaxel + RMC-6236 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + RMC-6236 Cetuximab + RMC-6236 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236	Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors	Recruiting	USA	0
NCT04034173	Phase II	Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation	Not yet recruiting	DEU	0
NCT03597581	Phase I	RGX202 Fluorouracil + Irinotecan + Leucovorin + RGX202 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202	A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer	Recruiting	USA	0
NCT03317119	Phase I	Trametinib + Trifluridine-tipiracil hydrochloride	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	Completed	USA	0
NCT02022982	Phase Ib/II	Palbociclib + PD-0325901	PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors	Completed	USA	0
NCT01306045	Phase II	Erlotinib Lapatinib MK2206 Sunitinib Selumetinib	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies	Completed	USA	0
NCT03162627	Phase I	Olaparib + Selumetinib	Selumetinib and Olaparib in Solid Tumors	Active, not recruiting	USA	0
NCT05564377	Phase II	Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Recruiting	USA	1
NCT04916236	Phase I	LY3214996 + RMC-4630	Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA)	Unknown status	NLD	0
NCT05379985	Phase I	RMC-6236	Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS	Recruiting	USA	0
NCT05907304	Phase I	LXH 254 + Trametinib	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (SEACRAFT-1)	Recruiting	USA \| GBR \| CAN \| AUS	1
NCT03745326	Phase Ib/II	Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients	Recruiting	USA	0
NCT05986071	Phase Ib/II	Fulvestrant + M1774	I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX)	Not yet recruiting	FRA	0
NCT04997902	Phase Ib/II	Alpelisib + Tipifarnib	Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)	Recruiting	USA	0
NCT03190941	Phase Ib/II	Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients	Recruiting	USA	0
NCT05512208	Phase II	Defactinib + RO5126766	A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK)	Recruiting	USA	0
NCT06104488	Phase I	RO5126766	A Study of Avutometinib for People With Solid Tumor Cancers	Recruiting	USA	0
NCT03919071	Phase II	Dabrafenib + Trametinib	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	Recruiting	USA	1
NCT02974803	Phase II	Dabrafenib + Trametinib	Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	Terminated	CAN	0
NCT02097225	Phase I	Dabrafenib + Onalespib + Trametinib	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Terminated	USA	0
NCT03310541	Phase I	Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant	AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations	Completed	USA	0
NCT05111561	Phase I	Binimetinib + ZEN-3694	Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	Suspended	USA	0
NCT05658640	Phase Ib/II	Cyclophosphamide + Cytarabine + Dexamethasone + Trametinib	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)	Recruiting	SWE \| NOR \| NLD \| ITA \| ISR \| IRL \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CHE \| BEL \| AUT	0
NCT06507306	Phase I	KQB198 + Osimertinib KQB198	A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies	Recruiting	USA	0
NCT04418167	Phase I	JSI-1187 Dabrafenib + JSI-1187	JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations	Suspended	USA	0
NCT05554328	Phase II	Selumetinib Olaparib + Selumetinib	Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT04487106	Phase II	Azacitidine + Trametinib + Venetoclax	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	Completed	USA	0
NCT04699188	Phase Ib/II	JDQ443 JDQ443 + TNO155 JDQ443 + Tislelizumab + TNO155 JDQ443 + Tislelizumab	Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	6
NCT06208124	Phase Ib/II	IMM-6-415	A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors	Recruiting	USA	0
NCT05340621	Phase Ib/II	Binimetinib + OKI-179	NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)	Active, not recruiting	USA	0
NCT02257424	Phase Ib/II	Dabrafenib + Hydroxychloroquine + Trametinib	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM)	Completed	USA	0
NCT05554380	Phase II	Ipatasertib + Paclitaxel	Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT04284774	Phase II	Tipifarnib	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Active, not recruiting	USA	1
NCT03114319	Phase I	TNO155	Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors	Active, not recruiting	USA \| NLD \| ITA \| ESP \| CAN	4
NCT03973918	Phase II	Binimetinib + Encorafenib	Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)	Terminated	USA	0

Gene Detail

Contact

Filtering

Sorting